GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the Company will present at two upcoming conferences data from BiomX's Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections. The findings will be presented in an oral pres ...

BiomX Inc. (NYSE:PHGE) Q1 2024 Earnings Conference Call May 21, 2024 8:00 AM ET Company Participants Jonathan Solomon - Chief Executive Officer Avi Gabay - Chief Financial Officer Conference Call Participants Joe Pantginis - HC Wainwright Yale Jen - Laidlaw & Co. Sohanna - Ladenburg Thalmann Operator Hello and welcome to the BiomX first quarter 2024 financial results. If anyone should require Operator assistance, please press star, zero on your telephone keypad. A question and answer session will follow the ...

GAITHERSBURG, Md. and NESS ZIONA, Israel, May 21, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided business and program updates for the first quarter ended March 31, 2024. BiomX is announcing merged financial reporting for the first time following the closing of its merger with Adaptive Phage Therapeutics, ...

Following merger with Adaptive Phage Therapeutics in March, combined company reports funding sufficient to support important data readouts for lead clinical programs in 2025 Company will host a conference call and webcast today at 8:00 am ET Cystic Fibrosis (BX004) In January 2024, the Company announced that BX004 was granted Orphan Drug Designation by the United States Food and Drug Administration ("FDA"), for the treatment of chronic pulmonary infection caused by P. aeruginosa in patients with CF. In Apri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38762 BiomX Inc. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 82-3364020 | | --- | --- | | (State or other jurisdict ...

GAITHERSBURG, Maryland and NESS ZIONA, Israel, May 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Tuesday, May 21, 2024, at 8:00 a.m. ET, to report first quarter 2024 financial results and provide business and program updates. To participate in the conference call, pl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission file number: 0001-38762 BIOMX INC. (Exact name of registrant as specified in its charter) | Delaware | 82-3364020 | | --- | --- | | (State or othe ...

BiomX Inc. (NYSE:PHGE) Q4 2023 Earnings Conference Call April 3, 2024 8:00 AM ET Company Participants Avi Gabay - Interim CFO Jonathan Solomon - CEO Conference Call Participants Joseph Pantginis - H.C. Wainwright Operator Good morning, and welcome to the BiomX Full Year 2023 Financial Results and Corporate Update Conference Call. Currently, all participants are in a listen-only mode. There will be a question-and-answer session at the end of this call. I'd now like to turn the conference over to Avi Gabay, I ...

Exhibit 99.1 BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Recent acquisition of Adaptive Phage Therapeutics creates leader in phage therapy with advanced, clinical-stage pipeline Closed concurrent $50 million financing to support BX004 and BX211 programs through key data readouts expected in 2025 Patient recruitment on track in BX211 Phase 2 trial in Diabetic Foot Osteomyelitis ("DFO"), with topline results expected in Q1 2025 Company will host a conference ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38762 BiomX Inc. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 82-3364020 | | --- | --- | | (State or other juris ...